NCT01275625

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 98 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy and safety of this combination in a Russian population of patients.

Conditions

• HIV

Interventions

Type	Name	Description
DRUG	HIV therapy	Combivir one tablet BD with maraviroc 300mg BD for 48 weeks

Timeline

• Start date: 2011-06-01
• Primary completion: 2012-10-01
• Completion: 2013-07-01
• First posted: 2011-01-12
• Last updated: 2014-03-03
• Results posted: 2014-03-03

Locations

8 sites across 1 country: Russia